Outlook Therapeutics Inc expected to post a loss of 83 cents a share - Earnings Preview

Outlook Therapeutics

18/12/2024 13:33

* Outlook Therapeutics Inc  OTLK.OQ   OTLK.O  is expected
to show
no change in quarterly revenue when it reports  results on
December 20 (estimated) for the period ending September 30 2024
    * 
    * ​LSEG's mean analyst estimate for Outlook Therapeutics Inc
is
for a loss of 83 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Outlook
Therapeutics Inc is $33.00​, above​ its last closing price
of $1.44. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -1.02       -1.00      -0.83     Beat    16.8
 Mar. 31 2024  -0.96       -0.85      -1.55     Missed  -82.4
 Dec. 31 2023  -0.92       -1.00      -0.80     Beat    20​
 Sep. 30 2023  -1.16       -1.17      -1.00     Beat    14.9
 ​​Jun.        -0.82       -1.03      -1.60     Missed  -55.6
 30 2023                                                
 Mar. 31 2023  -1.19       -1.30      -0.60     Beat    53.8​
 Dec. 31 2022  -1.00       -1.05      -1.60     Missed  -52.4
 Sep. 30 2022  -1.14       -1.35      -1.30     Beat    3.7
 This summary was machine generated December 18 at 13:32 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)